GEN News Highlights

OGT Takes Over Sense Proteomic to Bolster Biomarker Franchise

(OGT) has acquired Sense Proteomic to pad its biomarker discovery activities. Sense Proteomic uses a functional protein array technology for its research activities.

Sense Proteomic has reportedly identified autoantibody signatures for diagnosis and prognosis. The discovered autoantibodies may also be used to identify stage of a disease by monitoring the changes in production during disease progression, to monitor the response to therapeutic interventions, and to improve clinical outcomes by the stratification of patients for clinical trials and treatment. The firm reports that it has already found biomarker panels for several diseases including prostate cancer and systemic lupus erythematosus.

“This deal combined with our recent development of an ultrahigh-throughput DNA microarray facility gives OGT a unique blend of genomic and proteomic technologies and will lead to the development of biomarkers with profound clinical significance,” notes Mike Evans, OGT’s CEO.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.